| 1 | Cure after surgery for hepato-pancreato-biliary cancers: A systematic review | 2.5 | 5 | Citations (PDF) |
| 2 | Are there any benefits of prolonged hypothermic oxygenated perfusion?: Results from a national retrospective study | 2.5 | 12 | Citations (PDF) |
| 3 | Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma | 4.5 | 21 | Citations (PDF) |
| 4 | Recipient‐Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma—An ELTR Study | 3.9 | 8 | Citations (PDF) |
| 5 | Solitary necrotic nodule of the liver: imaging features, differential diagnosis and management | 2.8 | 1 | Citations (PDF) |
| 6 | Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy | 16.9 | 21 | Citations (PDF) |
| 7 | Liver transplantation for hepatitis D virus/hepatitis B virus coinfection in Italy: An intention-to-treat analysis of long-term outcomes | 4.5 | 2 | Citations (PDF) |
| 8 | Time to Expand Selection Criteria for MELD Exception Points in Liver Transplantation for Hepatocellular Carcinoma | 2.1 | 1 | Citations (PDF) |
| 9 | Intention-to-Treat Analysis of Hepatic Resection for Liver Metastases from Uveal Melanoma: A Single-Center Experience | 2.3 | 5 | Citations (PDF) |
| 10 | Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes of an International Analysis | 2.3 | 7 | Citations (PDF) |
| 11 | A snapshot on current approaches to lymphadenectomy in liver resection for intrahepatic cholangiocarcinoma: results from an international survey | 1.7 | 6 | Citations (PDF) |
| 12 | Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation | 4.2 | 61 | Citations (PDF) |
| 13 | Rescue pancreatic duct occlusion as pancreas-preserving procedure in case of emergency relaparotomy for grade C pancreatic fistulas after pancreaticoduodenectomy | 0.3 | 1 | Citations (PDF) |
| 14 | Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification | 16.8 | 228 | Citations (PDF) |
| 15 | Y90-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers | 16.8 | 34 | Citations (PDF) |
| 16 | Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications | 16.8 | 145 | Citations (PDF) |
| 17 | Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues | 3.8 | 34 | Citations (PDF) |
| 18 | Identification of
IGF2
as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma | 1.9 | 14 | Citations (PDF) |
| 19 | Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial) | 2.6 | 7 | Citations (PDF) |
| 20 | Transplantation for metastatic liver disease | 4.2 | 26 | Citations (PDF) |
| 21 | The role of ischaemia-reperfusion injury and liver regeneration in hepatic tumour recurrence | 4.5 | 32 | Citations (PDF) |
| 22 | Impact of Indocyanine Green Fluorescence Imaging on Lymphadenectomy Quality During Laparoscopic Distal Gastrectomy for Gastric Cancer (Greeneye): An Adaptative, Phase 2, Clinical Trial | 2.3 | 17 | Citations (PDF) |
| 23 | Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma | 4.5 | 7 | Citations (PDF) |
| 24 | The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors | 3.9 | 7 | Citations (PDF) |
| 25 | The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review | 0.9 | 38 | Citations (PDF) |
| 26 | Pancreaticoduodenectomy in octogenarians: The importance of “biological age” on clinical outcomes | 2.1 | 22 | Citations (PDF) |
| 27 | BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update | 4.2 | 3,979 | Citations (PDF) |
| 28 | The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality | 62.1 | 621 | Citations (PDF) |
| 29 | Impact of Surgical Margins on Overall Survival after Gastrectomy for Gastric Cancer: A Validation of Japanese Gastric Cancer Association Guidelines on a Western Series | 2.3 | 22 | Citations (PDF) |
| 30 | Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose–Response Analysis with Two Radiological Methods | 3.8 | 23 | Citations (PDF) |
| 31 | Migration rate using fully covered metal stent in anastomotic strictures after liver transplantation: Results from the BASALT study group | 3.9 | 8 | Citations (PDF) |
| 32 | Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma | 1.9 | 3 | Citations (PDF) |
| 33 | Variations in risk‐adjusted outcomes following 4318 laparoscopic liver resections | 2.8 | 10 | Citations (PDF) |
| 34 | Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study | 3.8 | 16 | Citations (PDF) |
| 35 | ENDOSCOPIC-RADIOLOGIC RENDEZ-VOUS CHOLEDOCHAL RECONSTRUCTION FOR THE TREATMENT OF POST-SURGICAL COMMON BILE DUCT TRANSECTION | 0.5 | 0 | Citations (PDF) |
| 36 | MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers | 4.1 | 9 | Citations (PDF) |
| 37 | Utility of the Iwate difficulty scoring system for laparoscopic right posterior sectionectomy: do surgical outcomes differ for tumors in segments VI and VII? | 2.3 | 5 | Citations (PDF) |
| 38 | The prognostic effect of adequate lymphadenectomy in clinically node-negative patients undergoing liver resection for intrahepatic cholangiocarcinoma | 4.2 | 3 | Citations (PDF) |
| 39 | Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria | 9.1 | 24 | Citations (PDF) |
| 40 | Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial | 0.3 | 83 | Citations (PDF) |
| 41 | Indocyanine Green Fluorescence-Guided Surgery for Gastrointestinal Tumors: A Systematic Review | 1.4 | 24 | Citations (PDF) |
| 42 | Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision | 3.8 | 23 | Citations (PDF) |
| 43 | DNA Methylation Profiling of Human Hepatocarcinogenesis | 10.1 | 93 | Citations (PDF) |
| 44 | Laparoscopic and open liver resection for hepatocellular carcinoma with Child–Pugh B cirrhosis: multicentre propensity score-matched study | 0.3 | 121 | Citations (PDF) |
| 45 | Resection of Retro-Hepatic Vena Cava (RHVC) En-bloc with Caudate Lobe without Vascular Exclusion for a Low Grade Leiomyosarcoma of Inferior Vena Cava | 2.3 | 3 | Citations (PDF) |
| 46 | Liver resection for perihilar cholangiocarcinoma: Impact of biliary drainage failure on postoperative outcome. Results of an Italian multicenter study | 1.8 | 25 | Citations (PDF) |
| 47 | Improved management of grade B biliary leaks after complex liver resections using gadoxetic acid disodium–enhanced magnetic resonance cholangiography | 1.8 | 4 | Citations (PDF) |
| 48 | Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors | 2.1 | 24 | Citations (PDF) |
| 49 | The Italian Consensus on minimally invasive simultaneous resections for synchronous liver metastasis and primary colorectal cancer: A Delphi methodology | 1.7 | 42 | Citations (PDF) |
| 50 | Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma | 3.6 | 8 | Citations (PDF) |
| 51 | In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells | 4.4 | 6 | Citations (PDF) |
| 52 | No benefit after neoadjuvant chemoradiation in stage IV rectal cancer: A propensity score-matched analysis on a real-world population | 2.5 | 4 | Citations (PDF) |
| 53 | Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study | 2.5 | 35 | Citations (PDF) |
| 54 | Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. 2021, 9, e003311 | | 200 | Citations (PDF) |
| 55 | Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation | 6.4 | 20 | Citations (PDF) |
| 56 | Transplant Oncology in Primary and Metastatic Liver Tumors | 4.6 | 74 | Citations (PDF) |
| 57 | Is minimally invasive liver surgery a reasonable option in recurrent HCC? A snapshot from the I Go MILS registry | 1.7 | 15 | Citations (PDF) |
| 58 | Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads | 1.7 | 2 | Citations (PDF) |
| 59 | Quantitative assessment of the impact of COVID-19 pandemic on pancreatic surgery: an Italian multicenter analysis of 1423 cases from 10 tertiary referral centers | 1.7 | 8 | Citations (PDF) |
| 60 | Immunotherapies for hepatocellular carcinoma | 70.7 | 1,625 | Citations (PDF) |
| 61 | Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis | 4.2 | 144 | Citations (PDF) |
| 62 | Risk-adjusted benchmarks in laparoscopic liver surgery in a national cohort | 0.3 | 48 | Citations (PDF) |
| 63 | Multicentre evaluation of case volume in minimally invasive hepatectomy | 0.3 | 25 | Citations (PDF) |
| 64 | The chances of hepatic resection curing hepatocellular carcinoma | 4.2 | 74 | Citations (PDF) |
| 65 | Response and relapse rates after treatment with long‐acting somatostatin analogs in multifocal or recurrent type‐1 gastric carcinoids: A systematic review and meta‐analysis | 4.8 | 28 | Citations (PDF) |
| 66 | mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors | 4.6 | 136 | Citations (PDF) |
| 67 | A Combined Approach to Priorities of Surgical Oncology During the COVID-19 Epidemic | 4.6 | 17 | Citations (PDF) |
| 68 | Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion – a multi‐center retrospective cohort study | 2.0 | 63 | Citations (PDF) |
| 69 | Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma | 6.8 | 56 | Citations (PDF) |
| 70 | Minimally Invasive Stage 1 to Protect Against the Risk of Liver Failure: Results from the Hepatocellular Carcinoma Series of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Italian Registry | 1.6 | 21 | Citations (PDF) |
| 71 | Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Retransplant | 8.8 | 101 | Citations (PDF) |
| 72 | Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship | 5.5 | 64 | Citations (PDF) |
| 73 | Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial | 27.4 | 309 | Citations (PDF) |
| 74 | Liver resection and transplantation for intrahepatic cholangiocarcinoma | 4.2 | 333 | Citations (PDF) |
| 75 | Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant | 4.2 | 74 | Citations (PDF) |
| 76 | HCC recurrence in HCV‐infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a
post‐hoc
analysis | 2.0 | 5 | Citations (PDF) |
| 77 | Preoperative predictors of liver decompensation after mini-invasive liver resection | 2.3 | 13 | Citations (PDF) |
| 78 | Liver transplantation as last-resort treatment for patients with bile duct injuries following cholecystectomy: a multicenter analysis | 0.5 | 1 | Citations (PDF) |
| 79 | Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial | 16.8 | 299 | Citations (PDF) |
| 80 | Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials | 5.5 | 85 | Citations (PDF) |
| 81 | Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma | 3.4 | 20 | Citations (PDF) |
| 82 | Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation | 4.5 | 83 | Citations (PDF) |
| 83 | Comparison Between Swan-Ganz Catheter and Minimally Invasive Hemodynamic Monitoring During Liver Transplantation: Report of a Monocentric Case Series | 0.7 | 3 | Citations (PDF) |
| 84 | Heterologous and cross-species tropism of cancer-derived extracellular vesicles | 11.3 | 64 | Citations (PDF) |
| 85 | Microenvironment and tumor inflammatory features improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms | 3.3 | 42 | Citations (PDF) |
| 86 | Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma | 2.1 | 17 | Citations (PDF) |
| 87 | The Italian Rare Pancreatic Exocrine Cancer Initiative | 1.4 | 7 | Citations (PDF) |
| 88 | A national mandatory-split liver policy: A report from the Italian experience | 4.5 | 74 | Citations (PDF) |
| 89 | First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma | 25.1 | 242 | Citations (PDF) |
| 90 | Permanent Pancreatic Duct Occlusion With Neoprene-based Glue Injection After Pancreatoduodenectomy at High Risk of Pancreatic Fistula | 4.6 | 32 | Citations (PDF) |
| 91 | Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice | 11.0 | 129 | Citations (PDF) |
| 92 | Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases | 2.6 | 8 | Citations (PDF) |
| 93 | Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation | 0.3 | 39 | Citations (PDF) |
| 94 | Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection | 0.9 | 18 | Citations (PDF) |
| 95 | Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs) | 4.3 | 27 | Citations (PDF) |
| 96 | Endo‐therapies for biliary duct‐to‐duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey | 3.9 | 23 | Citations (PDF) |
| 97 | Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations | 16.8 | 206 | Citations (PDF) |
| 98 | Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease | 10.1 | 630 | Citations (PDF) |
| 99 | Surgical Management of Hepatic Benign Disease: Have the Number of Liver Resections Increased in the Era of Minimally Invasive Approach? Analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry | 1.7 | 7 | Citations (PDF) |
| 100 | The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons | 6.7 | 33 | Citations (PDF) |
| 101 | pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma | 5.4 | 65 | Citations (PDF) |
| 102 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study | 27.4 | 341 | Citations (PDF) |
| 103 | EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma | 4.2 | 8,194 | Citations (PDF) |
| 104 | Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry | 0.3 | 62 | Citations (PDF) |
| 105 | Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry | 2.0 | 49 | Citations (PDF) |
| 106 | Alpha‐fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better | 10.1 | 10 | Citations (PDF) |
| 107 | Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion | 4.2 | 134 | Citations (PDF) |
| 108 | Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues | 0.9 | 84 | Citations (PDF) |
| 109 | Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients | 0.7 | 18 | Citations (PDF) |
| 110 | Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials | 5.5 | 20 | Citations (PDF) |
| 111 | Pro (With Caution): Extended oncologic indications in liver transplantation | 2.5 | 32 | Citations (PDF) |
| 112 | Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma | 0.9 | 624 | Citations (PDF) |
| 113 | Laparoscopic liver resection of hepatocellular carcinoma located in unfavaroble segments: a propensity score-matched analysis from the Italian group of minimally invasive liver surgery registry | 0.3 | 0 | Citations (PDF) |
| 114 | Hepatocellular Carcinoma in Abernethy Malformation: A Rare Occurrence of Congenital Complete Portosystemic Shunt | 1.1 | 5 | Citations (PDF) |
| 115 | Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma | 4.6 | 216 | Citations (PDF) |
| 116 | Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection | 4.2 | 522 | Citations (PDF) |
| 117 | Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma | 6.8 | 83 | Citations (PDF) |
| 118 | Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis | 2.9 | 16 | Citations (PDF) |
| 119 | A Longitudinal Investigation of Posttraumatic Growth and Quality of Life in Liver Transplant Recipients | 0.9 | 17 | Citations (PDF) |
| 120 | Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases? | 1.7 | 37 | Citations (PDF) |
| 121 | Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry | 2.3 | 53 | Citations (PDF) |
| 122 | Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma | 5.5 | 338 | Citations (PDF) |
| 123 | Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals | 4.2 | 8 | Citations (PDF) |
| 124 | Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry | 2.1 | 109 | Citations (PDF) |
| 125 | Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features | 0.9 | 856 | Citations (PDF) |
| 126 | Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey | 2.5 | 18 | Citations (PDF) |
| 127 | Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation | 0.9 | 373 | Citations (PDF) |
| 128 | Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver | 0.9 | 65 | Citations (PDF) |
| 129 | A matched pair analysis of multicenter longterm follow‐up after split‐liver transplantation with extended right grafts | 2.5 | 25 | Citations (PDF) |
| 130 | Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma | 0.3 | 24 | Citations (PDF) |
| 131 | Donor safety in living donor liver donation: An Italian multicenter survey | 2.5 | 66 | Citations (PDF) |
| 132 | Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases | 2.6 | 15 | Citations (PDF) |
| 133 | Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre‐ to post‐liver transplant: a real‐life strategy | 3.9 | 10 | Citations (PDF) |
| 134 | Thrombosis after liver transplantation for hepatocellular carcinoma | 2.3 | 9 | Citations (PDF) |
| 135 | Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis | 2.3 | 71 | Citations (PDF) |
| 136 | Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: A multicentre randomised clinical trial | 4.9 | 73 | Citations (PDF) |
| 137 | The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors | 4.5 | 210 | Citations (PDF) |
| 138 | Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma | 0.3 | 156 | Citations (PDF) |
| 139 | Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma | 3.9 | 31 | Citations (PDF) |
| 140 | Drug‐eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma | 2.5 | 81 | Citations (PDF) |
| 141 | External validation of an individual prognostic calculator after transarterial chemoembolization for hepatocellular carcinoma | 3.9 | 4 | Citations (PDF) |
| 142 | Importance of primary indication and liver function between stages: results of a multicenter Italian audit of ALPPS 2012–2014 | 0.3 | 65 | Citations (PDF) |
| 143 | Endoscopic ultrasound-guided esophagoenterostomy for a completely obstructed surgical anastomosis | 0.5 | 25 | Citations (PDF) |
| 144 | Endoscopic ultrasound-guided fine needle aspiration of splenic vein thrombosis: a novel approach to the portal venous system | 0.5 | 5 | Citations (PDF) |
| 145 | Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment | 10.1 | 358 | Citations (PDF) |
| 146 | Effect of age on survival in patients undergoing resection of hepatocellular carcinoma | 0.3 | 60 | Citations (PDF) |
| 147 | Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma | 8.8 | 155 | Citations (PDF) |
| 148 | Expert opinion on advanced techniques for hemostasis in liver surgery | 0.9 | 9 | Citations (PDF) |
| 149 | Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma | 2.1 | 420 | Citations (PDF) |
| 150 | Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma | 6.8 | 224 | Citations (PDF) |
| 151 | Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors | 2.5 | 9 | Citations (PDF) |
| 152 | Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma | 3.9 | 2 | Citations (PDF) |
| 153 | Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases | 2.3 | 25 | Citations (PDF) |
| 154 | Authors’ response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong
et al | 16.8 | 5 | Citations (PDF) |
| 155 | Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma | 13.7 | 285 | Citations (PDF) |
| 156 | DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma | 10.1 | 434 | Citations (PDF) |
| 157 | Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma | 0.9 | 122 | Citations (PDF) |
| 158 | Repeated transarterial chemoembolization: An overfitting effort? | 4.2 | 20 | Citations (PDF) |
| 159 | Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation | 4.2 | 78 | Citations (PDF) |
| 160 | Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology | 5.5 | 146 | Citations (PDF) |
| 161 | Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review | 2.3 | 9 | Citations (PDF) |
| 162 | Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets | 25.2 | 1,682 | Citations (PDF) |
| 163 | Liver transplantation for neuroendocrine tumour liver metastases | 0.3 | 97 | Citations (PDF) |
| 164 | Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial | 27.4 | 1,036 | Citations (PDF) |
| 165 | When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations | 0.3 | 63 | Citations (PDF) |
| 166 | Metformin Impact on Progression-Free Survival in Advanced Pancreatic Well-Differentiated Neuroendocrine Tumors (Pwdnets). Retrospective Evaluation in Diabetic Patients Receiving Everolimus Plus Octreotide Lar Treatment | 9.9 | 0 | Citations (PDF) |
| 167 | Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation | 3.1 | 67 | Citations (PDF) |
| 168 | Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study | 9.9 | 69 | Citations (PDF) |
| 169 | Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular Carcinoma | 4.5 | 61 | Citations (PDF) |
| 170 | Hepatocellular carcinoma: clinical frontiers and perspectives | 16.8 | 1,282 | Citations (PDF) |
| 171 | Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1–FEV translocation | 3.6 | 24 | Citations (PDF) |
| 172 | Current challenges in liver transplantation for hepatocellular carcinoma | 2.7 | 32 | Citations (PDF) |
| 173 | A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study | 2.5 | 21 | Citations (PDF) |
| 174 | Thoracic paravertebral anesthesia for percutaneous radiofrequency ablation of hepatic tumors | 3.1 | 27 | Citations (PDF) |
| 175 | A Prospective Policy Development to Increase Split-Liver Transplantation for 2 Adult Recipients | 4.6 | 62 | Citations (PDF) |
| 176 | Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinical–Radiological Outcomes and Safety Profile | 1.7 | 71 | Citations (PDF) |
| 177 | Intrahepatic Flow Redistribution in Patients Treated with Radioembolization | 1.7 | 22 | Citations (PDF) |
| 178 | Surgical management of duodenal stump fistula after elective gastrectomy for malignancy: an Italian retrospective multicenter study | 3.4 | 38 | Citations (PDF) |
| 179 | Carcinoid syndrome | 1.3 | 0 | Citations (PDF) |
| 180 | Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study | 4.9 | 239 | Citations (PDF) |
| 181 | Transhepatic anterior approach to the inferior vena cava in large retroperitoneal tumors resected en bloc with the right liver lobe | 1.8 | 15 | Citations (PDF) |
| 182 | Multiagent imaging of liver tumors with reference to intra-arterial radioembolization | 1.3 | 3 | Citations (PDF) |
| 183 | Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study | 4.2 | 152 | Citations (PDF) |
| 184 | Prognostic Role of Pancreatic Metastases From Renal Cell Carcinoma: Results From an Italian Center | 2.3 | 41 | Citations (PDF) |
| 185 | Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes | 0.9 | 529 | Citations (PDF) |
| 186 | Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives | 10.1 | 175 | Citations (PDF) |
| 187 | Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study | 10.1 | 474 | Citations (PDF) |
| 188 | Resection of hepatocellular cancer ≤2 cm: Results from two Western centers | 10.1 | 395 | Citations (PDF) |
| 189 | Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions | 3.1 | 552 | Citations (PDF) |
| 190 | Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy | 5.5 | 101 | Citations (PDF) |
| 191 | Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum | 3.8 | 7 | Citations (PDF) |
| 192 | Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection | 0.4 | 14 | Citations (PDF) |
| 193 | Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma | 2.3 | 65 | Citations (PDF) |
| 194 | Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib | 6.8 | 287 | Citations (PDF) |
| 195 | Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses | 4.2 | 116 | Citations (PDF) |
| 196 | Liver transplantation for unresectable hepatocellular carcinoma in normal livers | 4.2 | 54 | Citations (PDF) |
| 197 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial | 4.2 | 798 | Citations (PDF) |
| 198 | P1.24 Loss of Succinate Dehydrogenase in Midgut Carcinoids as Prognostic Factor: A New Marker of Personalized Cancer Medicine in Neuroendocrine Tumours? | 9.9 | 0 | Citations (PDF) |
| 199 | Liver Retransplantation in Adults: The Largest Multicenter Italian Study | 2.3 | 24 | Citations (PDF) |
| 200 | Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma | 0.9 | 424 | Citations (PDF) |
| 201 | MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a | 0.9 | 213 | Citations (PDF) |
| 202 | Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor–recipient matching | 2.5 | 73 | Citations (PDF) |
| 203 | Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization | 9.5 | 493 | Citations (PDF) |
| 204 | Gene-expression signature of vascular invasion in hepatocellular carcinoma | 4.2 | 141 | Citations (PDF) |
| 205 | Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients | 4.5 | 89 | Citations (PDF) |
| 206 | Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience | 2.5 | 535 | Citations (PDF) |
| 207 | Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: A review and consensus statement | 2.5 | 54 | Citations (PDF) |
| 208 | Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma | 2.3 | 59 | Citations (PDF) |
| 209 | Simultaneous characterization of progenitor cell compartments in adult human liver | 2.5 | 12 | Citations (PDF) |
| 210 | Duodenal Fistula after Elective Gastrectomy for Malignant Disease | 1.7 | 64 | Citations (PDF) |
| 211 | The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis | 2.0 | 49 | Citations (PDF) |
| 212 | 8. Multidisciplinary Approach for the Treatment of Neuroendocrine Tumors | 1.4 | 25 | Citations (PDF) |
| 213 | Massive APOBEC3 Editing of Hepatitis B Viral DNA in Cirrhosis | 4.4 | 151 | Citations (PDF) |
| 214 | IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage | 4.2 | 217 | Citations (PDF) |
| 215 | Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle | 4.2 | 84 | Citations (PDF) |
| 216 | miR-221 overexpression contributes to liver tumorigenesis | 7.5 | 711 | Citations (PDF) |
| 217 | CT cholangiography: Assessment of feasibility and diagnostic reliability | 2.8 | 13 | Citations (PDF) |
| 218 | Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo | 4.2 | 215 | Citations (PDF) |
| 219 | Characterization of stem cell compartments in adult human liver | 2.5 | 0 | Citations (PDF) |
| 220 | Hepatic stem cell characterization in tumoral and non-tumoral liver specimens from patients with hepatocellular carcinoma | 2.5 | 0 | Citations (PDF) |
| 221 | Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis | 27.4 | 2,189 | Citations (PDF) |
| 222 | Milan criteria, up-to-seven criteria, and the illusion of a rescue package for patients with liver cancer – Authors' reply | 27.4 | 1 | Citations (PDF) |
| 223 | Liver Transplantation for Hepatocellular Carcinoma | 2.3 | 261 | Citations (PDF) |
| 224 | Sorafenib in Advanced Hepatocellular Carcinoma | 34.5 | 13,773 | Citations (PDF) |
| 225 | Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma | 0.9 | 690 | Citations (PDF) |
| 226 | Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure | 2.0 | 53 | Citations (PDF) |
| 227 | Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma | 34.5 | 1,222 | Citations (PDF) |
| 228 | THE PLACE OF LIVER TRANSPLANTATION IN THE TREATMENT OF HEPATIC EPITHELOID HAEMANGIOENDOTHELIOMA: REPORT OF THE EUROPEAN LIVER TRANSPLANT REGISTRY (ELTR) | 2.1 | 0 | Citations (PDF) |
| 229 | Thyroid as a Target of Metastases. A Case of Foregut Neuroendocrine Carcinoma with Multiple Abdominal Metastases and a Thyroid Localization after 21 Years | 1.4 | 19 | Citations (PDF) |
| 230 | The Place of Liver Transplantation in the Treatment of Hepatic Epitheloid Hemangioendothelioma | 4.6 | 182 | Citations (PDF) |
| 231 | Phenomenology and Emotional Impact of Neuropsychiatric Symptoms in Orthotopic Liver Transplant for Hepatocellular Carcinoma | 0.7 | 3 | Citations (PDF) |
| 232 | First-Line Treatment for Hepatocellular Carcinoma: Resection or Transplantation? | 0.7 | 18 | Citations (PDF) |
| 233 | Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation | 4.2 | 83 | Citations (PDF) |
| 234 | Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation? | 4.2 | 332 | Citations (PDF) |
| 235 | Flow cytometry enumeration and characterization of stem cell lineages in the liver of patients with hepatic tumors | 2.5 | 0 | Citations (PDF) |
| 236 | Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma | 10.1 | 667 | Citations (PDF) |
| 237 | A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis | 0.9 | 387 | Citations (PDF) |
| 238 | Transthyretin RNA profiling in livers from transplanted patients affected by familial amyloidotic polyneuropathy, and identification of a dual transcription start point | 3.9 | 3 | Citations (PDF) |
| 239 | Percutaneous Transhepatic Biliary Drainage in the Management of Postsurgical Biliary Leaks in Patients with Nondilated Intrahepatic Bile Ducts | 1.7 | 72 | Citations (PDF) |
| 240 | Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis | 10.1 | 362 | Citations (PDF) |
| 241 | Split and whole liver transplantation outcomes: A comparative cohort study | 2.5 | 114 | Citations (PDF) |
| 242 | Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants | 2.5 | 78 | Citations (PDF) |
| 243 | ETOPOSIDE, CISPLATIN, EPIRUBICIN CHEMOTHERAPY IN THE TREATMENT OF PEDIATRIC LIVER TUMORS | 1.3 | 6 | Citations (PDF) |
| 244 | Resection and Liver Transplantation for Hepatocellular Carcinoma | 3.1 | 1,073 | Citations (PDF) |
| 245 | Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation | 4.6 | 470 | Citations (PDF) |
| 246 | Nonhepatic glucose production in humans | 3.0 | 66 | Citations (PDF) |
| 247 | Fibroblastic reticular cell tumor of the spleen: report of a case and review of the entity | 2.3 | 41 | Citations (PDF) |
| 248 | Assessment of insulin sensitivity based on a fasting blood sample in men with liver cirrhosis before and after liver transplantation1 | 2.1 | 15 | Citations (PDF) |
| 249 | Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer | 4.6 | 122 | Citations (PDF) |
| 250 | Candidates for liver transplantation for cancer: physical, psychological, and social conditions1 | 2.1 | 11 | Citations (PDF) |
| 251 | Feasibility of Peritonectomy Associated with Intraperitoneal Hyperthermic Perfusion in Patients with Pseudomyxoma Peritonei | 1.4 | 17 | Citations (PDF) |
| 252 | Resting energy expenditure in diabetic and nondiabetic patients with liver cirrhosis: relation with insulin sensitivity and effect of liver transplantation and immunosuppressive therapy | 4.7 | 43 | Citations (PDF) |
| 253 | Post-absorptive and insulin-mediated muscle protein metabolism in liver-transplanted patients | 2.2 | 6 | Citations (PDF) |
| 254 | Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment | 0.7 | 127 | Citations (PDF) |
| 255 | Liver transplantation for small hepatocellular carcinoma in cirrhosis: analysis of our experience | 0.7 | 56 | Citations (PDF) |
| 256 | Experience with radiofrequency ablation of small hepatocellular carcinomas before liver transplantation | 0.7 | 55 | Citations (PDF) |
| 257 | Resection versus transplantation for liver metastases from neuroendocrine tumors | 0.7 | 97 | Citations (PDF) |
| 258 | Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel ‘hot spot’ in codon 47 | 2.1 | 13 | Citations (PDF) |
| 259 | Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation | 10.1 | 126 | Citations (PDF) |
| 260 | Effect of TT Virus Infection on Hepatocellular Carcinoma Development: Results of a Euro‐Asian Survey | 3.7 | 38 | Citations (PDF) |
| 261 | Reply | 0.9 | 0 | Citations (PDF) |
| 262 | Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study11Data management by Italian Trials in Medical Oncology (I.T.M.O.) Scientific Service. | 1.5 | 56 | Citations (PDF) |
| 263 | RECURRENCE OF DESMOID TUMOR IN A MULTIVISCERAL TRANSPLANT PATIENT WITH GARDNER'S SYNDROME | 2.1 | 15 | Citations (PDF) |
| 264 | LIVER TRANSPLANTATION FOR RECURRENCE AFTER RESECTION OF SOLITARY HEPATOCELLULAR CARCINOMA | 2.1 | 2 | Citations (PDF) |
| 265 | Increased Retinol Binding Protein in the Sera of Patients with Severe Ischemic Damage of the Liver after Transplantation | 1.8 | 3 | Citations (PDF) |
| 266 | Pattern and management of recurrent hepatocellular carcinoma after liver transplantation | 2.0 | 139 | Citations (PDF) |
| 267 | Effect of liver transplantation in cirrhotic diabetic patients | 0.7 | 2 | Citations (PDF) |
| 268 | Bone Lesion in a Patient with Transplanted Liver for a Metastatic Carcinoid. The Role of Somatostatin Receptor Scintigraphy | 1.4 | 5 | Citations (PDF) |
| 269 | Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination | 0.7 | 92 | Citations (PDF) |
| 270 | Management of Complications from Hepatobiliary Surgery Using the Percutaneous Trans Jejunal Approach | 1.4 | 7 | Citations (PDF) |
| 271 | Renal-splenic shunt for intrahepatic caval occlusion after piggy-back liver transplantation | 2.0 | 3 | Citations (PDF) |
| 272 | Preoperative serum levels of wild-type and hepatitis B e antigen-negative hepatitis B virus (HBV) and graft infection after liver transplantation for HBV-related hepatocellular carcinoma | 1.9 | 6 | Citations (PDF) |
| 273 | Metabolic effects of liver transplantation in cirrhotic patients. | 10.6 | 46 | Citations (PDF) |
| 274 | Regulation of glucose homeostasis in humans with denervated livers. | 10.6 | 101 | Citations (PDF) |
| 275 | Psychosocial adaptation after liver transplantation with particularreference to recipients aware of their cancer | 0.9 | 4 | Citations (PDF) |
| 276 | Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis | 34.5 | 7,184 | Citations (PDF) |
| 277 | Risk of HBV reinfection after liver transplantation in HBsAg‐positive cirrhosis: Primary hepatocellular carcinoma is not a predictor for HBV recurrence | 0.0 | 23 | Citations (PDF) |
| 278 | Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus. | 10.6 | 67 | Citations (PDF) |
| 279 | A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group | 9.9 | 83 | Citations (PDF) |
| 280 | Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression | 2.0 | 4 | Citations (PDF) |
| 281 | Hepatic resection for hepatocellular carcinoma | 1.5 | 7 | Citations (PDF) |
| 282 | Reappraisal of the role of liver transplantation in the treatment of hepatocellular carcinoma arising in cirrhosis | 1.5 | 3 | Citations (PDF) |
| 283 | Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: The experience of the National Cancer Institute of Milan | 9.9 | 15 | Citations (PDF) |
| 284 | Liver transplantation (OLT) for small hepatocellular carcinoma (HCC) in cirrhosis | 10.1 | 2 | Citations (PDF) |
| 285 | HEPATOTROPHIC EFFECTS OF FK506 IN DOGS | 2.1 | 82 | Citations (PDF) |
| 286 | Effect of cyclosporine on hepatic energy status and on fructose metabolism after portacaval shunt in dog as monitored by phosphorus-31 nuclear magnetic resonance spectroscopyin vivo | 10.1 | 7 | Citations (PDF) |
| 287 | CHILDBEARING AFTER LIVER TRANSPLANTATION | 2.1 | 115 | Citations (PDF) |
| 288 | Hormonal and enzymatic parameters of hepatic regeneration in patients undergoing major liver resections | 10.1 | 60 | Citations (PDF) |
| 289 | A clinicopathologic study of primary hepatic carcinoid tumors | 4.0 | 93 | Citations (PDF) |
| 290 | hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis | 4.0 | 26 | Citations (PDF) |
| 291 | Inflammatory Pseudotumor of the Liver: Report of Two Cases | 1.4 | 16 | Citations (PDF) |
| 292 | Liver transplantation in patients with previous portasystemic shunt | 1.7 | 100 | Citations (PDF) |
| 293 | Reappraisal of surgical treatment of small hepatocellular carcinomas in cirrhosis: Clinicopathological study of resection or transplantation | 2.1 | 31 | Citations (PDF) |
| 294 | Estradiol and testosterone levels in patients undergoing partial hepatectomy | 2.1 | 47 | Citations (PDF) |
| 295 | The effect of estrogen and tamoxifen on hepatocyte proliferationin Vivo andin Vitro | 10.1 | 137 | Citations (PDF) |
| 296 | A Modified Technique of Orthotopic Transplant of the Kidney in Rabbits | 2.3 | 2 | Citations (PDF) |
| 297 | Efficacy of Liver Transplantation in Patients with Primary Biliary Cirrhosis | 34.5 | 239 | Citations (PDF) |
| 298 | HEPATIC ARTERY THROMBOSIS AFTER PEDIATRIC LIVER TRANSPLANTATION—A MEDICAL OR SURGICAL EVENT?1 | 2.1 | 229 | Citations (PDF) |
| 299 | Pharmacologic Modulation of Experimental Postischemic Hepatic Function | 4.6 | 34 | Citations (PDF) |
| 300 | Renal artery reconstruction for harvesting injuries in kidney transplantation with particular reference to the use of vascular allografts | 2.0 | 16 | Citations (PDF) |
| 301 | Occurrence of cytomegalovirus hepatitis in liver transplant patients | 3.6 | 63 | Citations (PDF) |
| 302 | Chordoma: Natural history and treatment results in 33 cases | 1.5 | 153 | Citations (PDF) |
| 303 | Primary lymphoma of the liver showing immunohistochemical evidence of T-cell origin | 2.1 | 30 | Citations (PDF) |
| 304 | Kaposi's sarcoma: Malignant tumor or proliferative disorder? | 0.7 | 14 | Citations (PDF) |
| 305 | Approach to Hepatic Metastases from Colorectal Adenocarcinoma | 3.1 | 3 | Citations (PDF) |
| 306 | Prolongation of Pig-to-Dog Renal Xenograft Survival by Modification of the Inflammatory Mediator Response | 4.6 | 42 | Citations (PDF) |
| 307 | Spontaneous Massive Necrosis of a Hepatocellular Carcinoma | 1.4 | 9 | Citations (PDF) |
| 308 | Title is missing! 0 | | 60 | Citations (PDF) |
| 309 | Hepatocellular carcinoma: Epidemiology, diagnosis and treatment | 4.5 | 59 | Citations (PDF) |
| 310 | Post-recurrence Survival After Liver Transplantation for Hepatocellular Carcinoma | 2.1 | 4 | Citations (PDF) |
| 311 | Aquaporin‐1 differentiates intrahepatic cholangiocarcinoma from liver metastases of pancreatic ductal adenocarcinoma | 3.6 | 0 | Citations (PDF) |
| 312 | Liver-directed surgical procedures during cytoreductive surgery for stage IV ovarian cancer | 0.9 | 1 | Citations (PDF) |
| 313 | Indocyanine green fluorescence for the intraoperative detection of extrahepatic hepatocellular carcinoma: a systematic review and pooled-analysis | 0.4 | 0 | Citations (PDF) |
| 314 | Immune-checkpoint inhibitors for advanced hepatocellular carcinoma in Child–Turcotte–Pugh-B cirrhosis: a liver-centric approach to outcomes beyond tumor progression | 4.2 | 0 | Citations (PDF) |
| 315 | Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions | 2.6 | 0 | Citations (PDF) |
| 316 | Rarity within rarity: complete response to chemoimmunotherapy in a patient with polymerase epsilon (POLE)-mutated locally advanced jejunal carcinoma | 3.4 | 0 | Citations (PDF) |
| 317 | Revisiting rejection after immune checkpoint inhibitor exposure prior to liver transplantation for hepatocellular carcinoma | 4.2 | 0 | Citations (PDF) |
